Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
pancreatitis/protease
Link salvestatakse lõikelauale
Leht 1 alates 22 tulemused
Test system for the determination of in-vivo active hemostasis proteases or of trypsin or subtilisin in biological fluids and/or the usage thereof to determine the in-vivo activation of hemostasis or to diagnose a pancreatitis
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
DESCRIPTION
Test system for the determination of in-vivo active hemostasis proteases or of trypsin or subtilisin in biological fluids and/or the usage thereof to determine the in-vivo activation of hemostasis or to diagnose a pancreatitis.
The present invention relates to a global procedure basing
Serine protease BSSP5
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The present application is the national stage under 35 U.S.C. .sctn.371 of international application PCT/JP99/06473, filed 19 Nov. 1999 which designated the United States, and which application was not published in the English language.
FIELD OF THE INVENTION
The present invention relates to
Test system for the determination of in-vivo active hemostasis proteases in biological fluids and/or the usage thereof to determine the in-vivo activation of hemostasis
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The present invention relates to a global procedure basing on peptide substrates for the determination of in-vivo active hemostasis proteases or of in-vivo active trypsin or of subtilisin in biological fluids, that particularly can be used to determine the in-vivo activation of hemostasis,
Protease variants for pharmaceutical use
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
REFERENCE TO A SEQUENCE LISTING
This application contains a Sequence Listing in computer readable form. The computer readable form is incorporated herein by reference.
TECHNICAL FIELD
The present invention relates to a protease having at least 90% identity to amino acids 1-188 of SEQ ID NO: 1, and
Therapeutic application of Kazal-type serine protease inhibitors
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
This is a national stage entry of PCT/EP2008/001009, filed Feb. 11, 2008, which claims priority to EP 07002903.8, filed Feb. 12, 2007, all of which are incorporated herein by reference.
The subject of the present invention is, in the most general aspect, the therapeutic application of the Kazal-type
Derivatives, having an inhibitory action against protease and an antiphlogistic action, of the trypsin-kallikrein inhibitor obtained from cattle organs (BPTI), their preparation and their use as medicaments
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The present invention relates to new derivatives of trypsin-kallikrein inhibitor, obtainable from cattle organs, which is called BPTI (basic pancreatic trypsin inhibitor [Kunitz]) in the text which follows, and to processes for the preparation of these derivatives from natural BPTI or from
Azetidin-2-one derivatives as serine protease inhibitors
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to novel 3-guanidinoalkyl-2-azetidinones useful for anti-thrombin and anti-trypsin activity.
2. Description of Related Art
The traditional use of compounds containing beta-lactam structures has been for antibacterial
Azetidin-2-one derivatives as serine protease inhibitors
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to novel 3-guanidinoalkyl-2-azetidinones useful for anti-thrombin and anti-trypsin activity.
2. Description of Related Art
The traditional use of compounds containing beta-lactam structures has been for antibacterial
Azetidin-2-one derivatives as serine protease inhibitors
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to novel 3-guanidinoalkyl-2-azetidinones useful for anti-thrombin and anti-trypsin activity.
2. Description of Related Art
The traditional use of compounds containing beta-lactam structures has been for antibacterial
Azetidin-2-one derivatives as serine protease inhibitors
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to novel 3-guanidinoalkyl-2-azetidinones useful for anti-thrombin and anti-trypsin activity.
2. Description of Related Art
The traditional use of compounds containing beta-lactam structures has been for antibacterial
Azetidin-2-one derivatives as serine protease inhibitors
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to novel 3-guanidinoalkyl-2-azetidinones useful for anti-thrombin and anti-trypsin activity.
2. Description of Related Art
The traditional use of compounds containing beta-lactam structures has been for antibacterial
Phenyl guanidinobenzoate derivatives which have protease inhibitory activity
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to novel benzoyl esters and acid addition salts thereof which have the inhibitory activities against proteases and are thus useful as a medicine.
2. Description of the Prior Art
It is known that various guanidinobenzoic
Lipase variants for pharmaceutical use
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
REFERENCE TO A SEQUENCE LISTING
This application contains a Sequence Listing in computer readable form. The computer readable form is incorporated herein by reference.
TECHNICAL FIELD
The present invention relates to a lipase for use as a medicament, which lipase (a) has at least 50% identity to the
Lipase variants for pharmaceutical use
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
REFERENCE TO A SEQUENCE LISTING
This application contains a Sequence Listing in computer readable form. The computer readable form is incorporated herein by reference.
TECHNICAL FIELD
The present invention relates to a lipase for use as a medicament, which lipase (a) has at least 50% identity to the
Lipase variants for pharmaceutical use
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
REFERENCE TO A SEQUENCE LISTING
This application contains a Sequence Listing in computer readable form. The computer readable form is incorporated herein by reference.
TECHNICAL FIELD
The present invention relates to a lipase for use as a medicament, which lipase (a) has at least 50% identity to the
Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus
- Töötab 55 keeles
- Taimsed ravimid, mida toetab teadus
- Maitsetaimede äratundmine pildi järgi
- Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
- Lugege oma otsinguga seotud teaduspublikatsioone
- Otsige ravimtaimi nende mõju järgi
- Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega
Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel
